Premio Nacional de Innovación_Inmunotek

INMUNOTEK receives the National Innovation Award

Their Majesties the Kings of Spain present INMUNOTEK with the National Innovation Award in the Small and Medium-Sized Entities (SME) category. The act presided over by the Kings took place at the Valencia Science Museum. It was attended by the Minister of Science and Innovation, Pedro Duque, local authorities. jury and guests. The National Innovation Award is the highest award given by the Government of Spain to recognize those entities that make innovation their main business growth strategy.


INMUNOTEK innovative entity granted by BLOCKPCT

INMUNOTEK obtains the certificate as innovative entity in the private and independent blockchain network of the Spanish Science and Technology Parks (BLOCKPCT) promoted by the Association of Science and Technology Parks of Spain (APTE).


Supply of Products and COVID-19

INMUNOTEK has implemented action measures to minimize the impact that the COVID-19 crisis is having due to the confinement situation established in Spain with the aim of guaranteeing the supply of its products to patients.



The MV130 project presented by INMUNOTEK has been selected by ITTN (International Technology Transfer Network) among more than 300 international projects for the first Roadshow sponsored by CAST (China Association for Science and Technology) in the fight against COVID-19. MV130 induces trained immunity and confers resistance to viral infections by activating innate immunity in a stable way through metabolic and epigenetic changes on innate immune cells.

Financial Times

Financial Times features INMUNOTEK

, , ,

Financial Times features INMUNOTEK as an example of a Spanish company with strong growth along the years even in unfavorable situations. According to the economic newspaper, the strength of these companies is based on their commitment to innovation and competitiveness. This allows to focus its productive activity towards foreign markets, have a sustained growth and create employment.

MyTomorrows and INMUNOTEK collaboration

myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and INMUNOTEK announced a collaboration to develop an Expanded Access Program (EAP) for the unlicensed bacterial vaccine Uromune.

logo PNID2

National Innovation Award to INMUNOTEK

, , ,

The Spanish Ministry of Science, Innovation and Universities has awarded INMUNOTEK the National Innovation Award 2019. This price, the highest award granted in Spain to distinguish companies that make innovation their main business growth strategy, is endowed with 30,000 euros and has been granted to INMUNOTEK in the category of “Small and Medium-Sized Enterprise”.

Cepyme Premio 2019

INMUNOTEK awarded as “Best SME of the Year”

, , ,

INMUNOTEK has been awarded as the Best SME of the Year 2019 by CEPYME (Spanish Confederation of Small and Medium-Sized Enterprises). This award recognizes Business Excellence under the criteria of business activity, innovation, internationalization and job creation. The award ceremony was chaired by the Spanish Minister of Economy and Business, Nadia Calviño, the President of CEPYME, Gerardo Cuerva and the CEO of Santander Bank, Rami Aboukhair, as sponsor of the award.

EAACI 2019 logo

INMUNOTEK at the EAACI congress

INMUNOTEK has been present at the EAACI congress held in Lisbon in the commercial exhibition area. The annual conference of the EAACI (European Academy of Allergy and Clinical Immunology) is one of the most important events in the field of allergy and immunology worldwide. With a participation of more than 7,000 delegates and a high scientific and commercial level, the annual congress is the most outstanding event of the EAACI.

Comunidad Madrid

Visit of the Regional Minister of Health

The Regional Minister of Health of the Community of Madrid, Enrique Ruiz Escudero, has visited INMUNOTEK after receiving the CEIM award as the best innovative company. The visit was accompanied by Luisa María Fernanda, General Director of Madrid Activa. After a presentation of the company by José Luis Subiza, CEO-President of INMUNOTEK, a visit was made to the production facilities and the R&D laboratories.